- Conditions
- Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma
- Interventions
- 225Ac-SSO110 + SoC, Atezolizumab, Durvalumab, Avelumab, Pembrolizumab, Retifanlimab
- Drug
- Lead sponsor
- Ariceum Therapeutics GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 6
- States / cities
- Miami, Florida • Louisville, Kentucky • Glen Burnie, Maryland + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 136
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Child Abuse
- Interventions
- Healthy Families Durham, Yearly Checkup
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- Female only
- Enrollment
- 343 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Merkel Cell Carcinoma, Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Cancer
- Interventions
- RP1, intra-tumoral injection, oncolytic virus
- Biological
- Lead sponsor
- Replimune, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 20 more
- Conditions
- Intestinal Permeability
- Interventions
- plant derived phenolics, Microcrystaline cellulose (MCC)
- Dietary Supplement · Other
- Lead sponsor
- Brightseed
- Industry
- Eligibility
- 30 Years to 69 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Addison, Illinois
- Conditions
- Primary Ciliary Dyskinesia (PCD)
- Interventions
- RCT1100
- Drug
- Lead sponsor
- ReCode Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Metastatic Solid Tumor, Brain Metastases
- Interventions
- Trastuzumab emtansine, Tucatinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ, Mycobacterium
- Interventions
- EN3348, Mitomycin C
- Biological
- Lead sponsor
- Bioniche Life Sciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 56
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 49 more
- Conditions
- Merkel Cell Carcinoma
- Interventions
- ITI-3000
- Drug
- Lead sponsor
- Immunomic Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- Trastuzumab Emtansine
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Kartagener Syndrome
- Interventions
- Not listed
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- Not listed
- Enrollment
- 1,800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2027
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Mood Disorders, Bipolar Disorder, Major Depression
- Interventions
- Family-Focused Treatment with MCC App
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 13 Years to 19 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- QTc Interval, Pharmacokinetics
- Interventions
- Psilocybin, Moxifloxacin, Micro-Crystalline Cellulose
- Drug
- Lead sponsor
- Usona Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Cancer
- Interventions
- Patient Navigator (PN), Baseline Questionnaire, Follow-up Questionnaire, Patient Navigator Satisfaction Survey
- Behavioral · Other
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Metastatic Breast Cancer
- Interventions
- Trastuzumab emtansine [Kadcyla] 3.0 mg/kg, Trastuzumab emtansine [Kadcyla] 3.6 mg/kg, Pertuzumab 420 mg
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 10
- States / cities
- Boca Raton, Florida • Deerfield Beach, Florida • Maywood, Illinois + 6 more
- Conditions
- Stage IIIB Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma
- Interventions
- aNK (NK-92), aNK (NK-92) + N-803
- Biological
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Pittsburgh, Pennsylvania • Seattle, Washington
- Conditions
- Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
- Interventions
- Multi-epitope HER2 Peptide Vaccine TPIV100, Pertuzumab, Placebo Administration, Sargramostim, Trastuzumab, Trastuzumab Emtansine
- Biological · Other
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 30
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 26 more
- Conditions
- Myocardial Infarction
- Interventions
- MCC-135
- Drug
- Lead sponsor
- Tanabe Pharma Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 414 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Staying Strong With Schools Intervention, Waitlist Control
- Interventions
- Staying Strong with Schools Intervention, Waitlist Control
- Behavioral · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 10
- States / cities
- Cambridge, Massachusetts • East Falmouth, Massachusetts • Falmouth, Massachusetts + 4 more
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
- Interventions
- Abemaciclib, Trastuzumab Emtansine
- Drug · Biological
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 6
- States / cities
- Yuma, Arizona • Jacksonville, Florida • Urbana, Illinois + 3 more
- Conditions
- Myeloma, Lymphoma, Leukemia
- Interventions
- EMR Tailoring, Survey Tailoring, Physician Involvement
- Behavioral
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Moderate to Severe Asthma
- Interventions
- 3% Hypertonic Saline, 7% Hypertonic Saline, Salbutamol
- Device · Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Merkel Cell Carcinoma
- Interventions
- GLA-SE
- Biological
- Lead sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Cystic Fibrosis
- Interventions
- Hypertonic Saline, Isotonic Saline, Indium-DTPA, Technetium Sulfur Colloid
- Drug
- Lead sponsor
- Tim Corcoran
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- COPD, Chronic Bronchitis
- Interventions
- tPAD, 7% hypertonic saline (510K approved as a device)
- Device
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 40 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina